Condition
SLL (Small Lymphocytic Lymphoma)
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07342478Phase 3Recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT01500733Phase 2Active Not Recruiting
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06708897Phase 1Recruiting
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
NCT06979076Phase 1Not Yet Recruiting
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
Showing all 4 trials